Dr. Elaine Sullivan

CEO Carrick Therapeutics

Dr. Elaine Sullivan is the CEO of Carrick Therapeutics, a new European Oncology company. She has over 25 years of international experience working in the Pharmaceutical industry in the US and the UK. Elaine has worked as part of top management R&D teams at Eli Lilly and AstraZeneca.

She is a Non-executive Director of the IP Group plc and is a Member of the Supervisory Board of Evotec AG.

Dr. Elaine Sullivan was the Vice President of Global External Research and Development at Eli Lilly and Company. She led a global workforce delivering access to business critical external innovation; by firstly identifying, evaluating and acquiring therapeutic molecules and technologies and secondly by creating and managing Lilly’s external R&D portfolio via venture, equity and strategic partnerships.

She was a member of the investment committees of Lilly Ventures and Lilly Asian Ventures and the steering committees of Lilly’s Capital Fund partners.

As Vice President, R&D New Opportunities, she led the first virtual Therapy Area in AstraZeneca. New Opportunities pinpointed new disease areas and future healthcare trends, created new therapeutic applications for multiple molecular entities and advanced them into the clinic.

As Vice President, Science & Technology at AstraZeneca, Elaine identified and integrated novel drug-hunting approaches, which successfully reduced compound attrition in the clinic and significantly decreased the time to deliver new molecules.

Dr. Sullivan received a bachelor’s degree in Molecular Biology from the University of Glasgow and a doctorate in Molecular Biology and Virology from the University of Edinburgh under the supervision of Professor Sir Ken Murray, FRS.